Search clinical trials for: REGN4461

Total 8 results

Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers

Healthy Volunteers

Belgium
Regeneron Pharmaceuticals

Available

Expanded Access to REGN4461 for Patients With Lipodystrophy or Monogenic Obesity With Complications of Leptin Deficiency or Deficient Leptin Signaling

Partial Lipodystrophy | Generalized Lipodystrophy | Monogenic Obesity Due to LEP or LEPR Loss of Function
Regeneron Pharmaceuticals

Active, not recruiting

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

Generalized Lipodystrophy

United States, Peru, Russian Federation, Turkey
Regeneron Pharmaceuticals

Active, not recruiting

A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) (LEAP)

Familial Partial Lipodystrophy | Metabolic Abnormalities

United States, France, Spain, Turkey, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers

Healthy

Australia
Regeneron Pharmaceuticals

Terminated

Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis

Pruritus | Atopic Dermatitis

Poland, Germany, Finland
Regeneron Pharmaceuticals
Sanofi

Completed

A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

United States
Eli Lilly and Company
Regeneron Pharmaceuticals

Not yet recruiting

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Obesity

United States, Mexico

3

Subscribe